Fischgrund Jeffrey S, Rhyne Alfred, Franke Jörg, Sasso Rick, Kitchel Scott, Bae Hyun, Yeung Christopher, Truumees Eeric, Schaufele Michael, Yuan Philip, Vajkoczy Peter, Depalma Michael, Anderson David G, Thibodeau Lee, Meyer Bernhard
Department of Orthopedic Surgery, Oakland University, William Beaumont School of Medicine, Royal Oak, Michigan.
OrthoCarolina Spine Center, Charlotte, North Carolina.
Int J Spine Surg. 2019 Apr 30;13(2):110-119. doi: 10.14444/6015. eCollection 2019 Apr.
The purpose of the present study is to report the 2-year clinical outcomes for chronic low back pain (CLBP) patients treated with radiofrequency (RF) ablation of the basivertebral nerve (BVN) in a randomized controlled trial that previously reported 1-year follow up.
A total of 147 patients were treated with RF ablation of the BVN in a randomized controlled trial designed to demonstrate safety and efficacy as part of a Food and Drug Administration-Investigational Device Exemption trial. Evaluations, including patient self-assessments, physical and neurological examinations, and safety assessments, were performed at 2 and 6 weeks, and 3, 6, 12, 18, and 24 months postoperatively. Participants randomized to the sham control arm were allowed to cross to RF ablation at 12 months. Due to a high rate of crossover, RF ablation treated participants acted as their own control in a comparison to baseline for the 24-month outcomes.
Clinical improvements in the Oswestry Disability Index (ODI), Visual Analog Scale (VAS), and the Medical Outcomes Trust Short-Form Health Survey Physical Component Summary were statistically significant compared to baseline at all follow-up time points through 2 years. The mean percent improvements in ODI and VAS compared to baseline at 2 years were 53.7 and 52.9%, respectively. Responder rates for ODI and VAS were also maintained through 2 years with patients showing clinically meaningful improvements in both: ODI ≥ 10-point improvement in 76.4% of patients and ODI ≥ 20-point improvement in 57.5%; VAS ≥ 1.5 cm improvement in 70.2% of patients.
Patients treated with RF ablation of the BVN for CLBP exhibited sustained clinical benefits in ODI and VAS and maintained high responder rates at 2 years following treatment. Basivertebral nerve ablation appears to be a durable, minimally invasive treatment for the relief of CLBP.
本研究旨在报告在一项先前已报道1年随访结果的随机对照试验中,接受椎基底神经(BVN)射频消融术治疗的慢性下腰痛(CLBP)患者的2年临床结局。
在一项旨在证明安全性和有效性的随机对照试验中,共有147例患者接受了BVN射频消融术,该试验是美国食品药品监督管理局器械临床试验豁免试验的一部分。在术后2周和6周以及3、6、12、18和24个月进行评估,包括患者自我评估、体格检查和神经学检查以及安全性评估。随机分配至假手术对照组的参与者在12个月时可转为接受射频消融术。由于交叉率较高,在比较24个月结局时,接受射频消融术治疗的参与者以自身作为对照与基线进行比较。
在长达2年的所有随访时间点上进行比较,Oswestry功能障碍指数(ODI)、视觉模拟量表(VAS)和医疗结局信任简短健康调查身体成分总结的临床改善与基线相比具有统计学意义。与基线相比,2年时ODI和VAS的平均改善百分比分别为53.7%和52.9%。ODI和VAS的有效率在2年期间也得以维持,患者在这两方面均显示出具有临床意义的改善:76.4%的患者ODI改善≥10分,57.5%的患者ODI改善≥20分;70.2%的患者VAS改善≥1.5 cm。
接受BVN射频消融术治疗CLBP的患者在ODI和VAS方面表现出持续的临床获益,且在治疗后2年维持了较高的有效率。椎基底神经消融术似乎是一种持久、微创的CLBP缓解治疗方法。